The Phase III STARGLO trial: Glofit-GemOx versus R-GemOx for R/R DLBCL
Published July 9, 2024
Views 1.08K | Likes 7 | Comments 0
At a glance
Views
1,089
Likes
7
Comments
0
Performance vs. channel
Outlier score
Engagement rate
More features coming
We're working on new analytics and tools. Stay tuned.
About
In this presentation, Jeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, discusses the Phase III STARGLO trial (NCT04408638), which compared the safety and efficacy of glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab-GemOx (R-GemOx) in patients with relapsed/refractory (R/R) dif…
- Published
- July 9, 2024
- Made for kids
- No
More features coming
We're working on new analytics and tools. Stay tuned.